Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana.
To evaluate the efficacy of the schedule currently recommended for immunization with trivalent oral poliovirus vaccine (TOPV) (i.e., at birth, 6 weeks, 10 weeks, and 14 weeks after birth), we randomly assigned 452 infants into test (231 infants) and control (221 infants) groups. The test group received TOPV as currently recommended, and the dose at birth was omitted for the control group. At 10, 14, and 18 weeks of age, the levels of poliovirus neutralizing antibodies as well as seroconversion rates were consistently higher for the test group than for the control group. The final seroconversion rates against poliovirus types 1, 2, and 3 were 83.5%, 91% and 83%, respectively, for the test group and 75%, 83.2%, and 79.1%, respectively, for the control group. The TOPV immunization schedule starting at birth therefore produced better results. Seroconversion rates as well as antibody levels were highest in infants with low maternal antibodies.
Osei-Kwasi
M
M
Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.
Afari
E A
EA
Mimura
K
K
Obeng-Ansah
I
I
Ampofo
W K
WK
Nkrumah
F K
FK
D000914:Antibodies, Viral / Q000302:isolation & purification; D005869:Ghana; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D017955:Poliovirus / Q000145:classification / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage* / Q000276:immunology; D012703:Serotyping; D016037:Single-Blind Method
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral